To date, benefit-cost analysis has rarely been used to justify the drug abuse prevention field.
However, there is an increasing demand for this type of analysis as the field of substance abuse prevention enters a new phase - a phase characterized by a competitive marketplace, an increased demand for accountability, and the desire to measure return on the money invested in prevention.
In response, an effort is made to stimulate discussion and further research on the topic.
This article first determines the overall strategy for initiating benefit-cost analysis (BCA), followed by definitions of BCA and cost-effectiveness analysis (CEA).
This is followed by the determination of some of the major variables used in BCA along with the algorithm for determining the benefit-cost efficiency ratio (R) as it applies to the macro level analysis.
In estimating a value for the R, a decision has been made to incorporate uncertainty into the BCA.
In a macroscopic approach to BCA, four independent variables are identified for computing R. These independent and dependent variables are assumed to be random variables with normal distributions.
The population means and standard deviations pertaining to these independent variables are estimated from the existing literature.
In order to incorporate uncertainty into the computation of R, ten measurements have been randomly selected for each of the four independent variables.
Mots-clés Pascal : Prévention, Programme sanitaire, Alcoolisme, Toxicomanie, Analyse coût, Analyse économique, Analyse avantage coût, Economie santé, Santé mentale, Etats Unis, Amérique du Nord, Amérique, Homme
Mots-clés Pascal anglais : Prevention, Sanitary program, Alcoholism, Drug addiction, Cost analysis, Economic analysis, Cost benefit analysis, Health economy, Mental health, United States, North America, America, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0449523
Code Inist : 002B18H05A. Création : 01/03/1996.